Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Oct 26, 2018
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Spectroscopy in Functional Assessment of Peripheral Artery Disease" (spectroAMI) is studying how well a special imaging technique called P-31 MR spectroscopy can help assess the function of mitochondria in patients with peripheral arterial occlusive disease (PAOD). This condition causes reduced blood flow to the legs, often leading to pain during physical activity (called claudication). By understanding mitochondrial function, researchers hope to find better ways to evaluate and treat this disease.
To participate in this trial, you should be between the ages of 65 and 75 and have been diagnosed with PAOD, specifically with a blockage in the main arteries of the leg. You must also have a specific measurement of blood flow in your legs (ABI) and be planning for surgery. However, some people may not qualify, such as those with certain medical devices like pacemakers, recent severe leg pain, or uncontrolled high blood pressure. If you join the study, you can expect to undergo non-invasive imaging tests and will be closely monitored by medical professionals. This research could help improve future treatments for people with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Peripheral arterial occlusive disease (PAOD) with claudication and surgery planning with proximal lesion (iliac or femoral (x-ray angiography or CT or MRA) and no distal lesions (doppler)
- • ABI\<0.90 or \>1.30
- • signed consent form
- • health insurance coverage
- Exclusion Criteria:
- • Contraindication in the practice of MRI: pacemaker, metallic cardiac valve, intra-ocular metal part, claustrophobia
- • critical ischemia \>15 days
- • Type 1 or 2 diabetes
- • weight \>200kg
- • non stabilized hypertension
- • beta-blockers
- • non-atherosclerotic vascular occlusive disease (Buerger disease, Takayasu disease, venous disease, trapped popliteal artery etc..)
- • Neurological pathology/non-voluntary contraction
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
Pierre CROISILLE, PhD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials